Less is more? De-intensification of therapy for early-stage HER2-positive breast cancer

被引：1
|
作者：
Mathew, Aju [1 ]
Brufsky, Adam [2 ]
机构：
[1] Univ Kentucky, Markey Canc Ctr, Lexington, KY USA
[2] Univ Pittsburgh, Med Ctr, Magee Womens Hosp, Pittsburgh, PA 15241 USA
来源：
LANCET ONCOLOGY | 2017年 / 18卷 / 04期
关键词：
OPEN-LABEL; TRASTUZUMAB; MULTICENTER; TRIAL;
D O I：
10.1016/S1470-2045(17)30150-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：428 / 429
页数：3
相关论文
共 50 条
  • [41] Effect of PREDICT on chemotherapy/trastuzumab recommendations in HER2-positive patients with early-stage breast cancer
    Down, Sue K.
    Lucas, Olivia
    Benson, John R.
    Wishart, Gordon C.
    [J]. ONCOLOGY LETTERS, 2014, 8 (06) : 2757 - 2761
  • [42] Can Less Be More? Evolving Strategies for Therapy De-escalation in Early-Stage Breast Cancer
    Speers, Corey
    Anderson, Bethany
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 119 (05): : 1327 - 1330
  • [43] Economic evaluation of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer: systematic review and quality assessment
    Genuino, Anne Julienne
    Gloria, Mac Ardy Junio
    Chaikledkaew, Usa
    Reungwetwattana, Thanyanan
    Thakkinstian, Ammarin
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (05) : 1001 - 1010
  • [44] POTENTIAL COST-EFFECTIVENESS OF NERATINIB FOLLOWING TRASTUZUMAB THERAPY FOR TREATMENT OF EARLY-STAGE HER2-POSITIVE BREAST CANCER
    Schwartz, N. R.
    Steuten, L.
    Babigumira, J. B.
    Roth, J. A.
    [J]. VALUE IN HEALTH, 2018, 21 : S28 - S28
  • [45] De-escalation of neoadjuvant therapy for HER2-positive early breast cancer: an overview
    Werutsky, Gustavo
    Rosa, Mahira Lopes
    [J]. ANNALS OF PALLIATIVE MEDICINE, 2020, 9 (04) : 1352 - 1357
  • [46] Increasing therapy options for HER2-positive early breast cancer
    Harbeck, Nadia
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2012, 9 (01) : 10 - 12
  • [47] Increasing therapy options for HER2-positive early breast cancer
    Nadia Harbeck
    [J]. Nature Reviews Clinical Oncology, 2012, 9 : 10 - 12
  • [48] Neratinib in adjuvant treatment of patients with HER2-positive breast cancer - less is more?
    Cedrych, Ewa
    Cedrych, Ida
    [J]. ONCOLOGY IN CLINICAL PRACTICE, 2019, 15 (02): : 111 - 114
  • [49] Towards personalized treatment for early stage HER2-positive breast cancer
    Goutsouliak, Kristina
    Veeraraghavan, Jamunarani
    Sethunath, Vidyalakshmi
    De Angelis, Carmine
    Osborne, C. Kent
    Rimawi, Mothaffar F.
    Schiff, Rachel
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2020, 17 (04) : 233 - 250
  • [50] Towards personalized treatment for early stage HER2-positive breast cancer
    Kristina Goutsouliak
    Jamunarani Veeraraghavan
    Vidyalakshmi Sethunath
    Carmine De Angelis
    C. Kent Osborne
    Mothaffar F. Rimawi
    Rachel Schiff
    [J]. Nature Reviews Clinical Oncology, 2020, 17 : 233 - 250
12345